Her major clinical and research interests are in the delivery of efficient and effective care for patients with amyloidosis, with a particular focus on new technologies: imaging and drugs. She is chief investigator and principal investigator in several clinical trials ranging from trials focusing on gene silencers targeting the amyloid production to trials testing monoclonal antibodies targeting the existing deposits. She works across the University and the Royal Free Hospital and interacts closely with industry. Major contributions include advances on the diagnosis, management and treatment of patients with cardiac amyloidosis. These achievements were recognised with numerous awards, including the Michael Davies Early Career Award in 2021 and the British Heart Foundation Fellow of the year award in 2022.